Switch to:

Arena Pharmaceuticals EPS (Diluted)

: $11.51 (TTM As of Jun. 2019)
View and export this data going back to 2000. Start your Free Trial

Arena Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2019 was $-1.24. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2019 was $11.51.

Arena Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2019 was $-1.24. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2019 was $11.98.

Arena Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2019 was $-1.24. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2019 was $11.51.

During the past 3 years, the average EPS without NRIGrowth Rate was 49.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 29.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Arena Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 57.10% per year. The lowest was -104.70% per year. And the median was 16.70% per year.


Arena Pharmaceuticals EPS (Diluted) Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Arena Pharmaceuticals Annual Data
Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EPS (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.80 -4.49 -0.93 -2.77 -0.63

Arena Pharmaceuticals Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19
EPS (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.65 -0.70 1.35 12.10 -1.24

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Arena Pharmaceuticals EPS (Diluted) Distribution

* The bar in red indicates where Arena Pharmaceuticals's EPS (Diluted) falls into.



Arena Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Arena Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2018 is calculated as

Diluted EPS (A: Dec. 2018 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-29.399-0)/47.041
=-0.62

Arena Pharmaceuticals's Diluted EPS for the quarter that ended in Jun. 2019 is calculated as

Diluted EPS (Q: Jun. 2019 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-61.403-0)/49.653
=-1.24

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2019 was -0.7 (Sep. 2018 ) + 1.35 (Dec. 2018 ) + 12.1 (Mar. 2019 ) + -1.24 (Jun. 2019 ) = $11.51

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Arena Pharmaceuticals  (NAS:ARNA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Arena Pharmaceuticals EPS (Diluted) Related Terms


Arena Pharmaceuticals EPS (Diluted) Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)